National Comprehensive Cancer Network guidelines currently recommend standard PD-L1 immunohistochemistry (IHC) testing in all advanced (stage IIIB and IV) lung squamous cell carcinomas and adenocarcinomas for selection of frontline pembrolizumab therapy [8]. This evidence concerns the gene CD274 and adenocarcinoma.